title: Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents.
abstract: Paediatric multiple sclerosis (MS) accounts for up to 5% of all MS cases. No therapies have been formally approved for paediatric patients with MS. However, there is published experience on the use of disease modifying therapies in children and adolescents with MS. Neuromyelitis optica (NMO) is an autoimmune inflammatory disease preferentially targeting the optic nerves and spinal cord. This devastating disease usually requires preventive therapy with a range of immunosuppressive medications. There are limited studies informing the use of these medications in children with NMO. This review provides a comprehensive analysis of the published literature on therapeutic interventions in children and adolescents with MS and NMO.
authors: Paediatric Multiple Sclerosis Clinic, Paediatric Neurologist, National Paediatric Hospital Dr. Juan P. Garrahan, Buenos Aires 1245, Argentina. Electronic address: silviatenembaum@gmail.com.
authors: Silvia N
authors: SN
authors: Tenembaum
mesh_terms: D000293:Adolescent; D001323:Autoantibodies / Q000097:blood; D002648:Child; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D009900:Optic Nerve / Q000187:drug effects / Q000276:immunology* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D007166:Immunosuppressive Agents
keywords: Childhood; Disease modifying therapies; Immunosuppressive agents; Multiple sclerosis; Neuromyelitis optica